CN102348718B - 去氧阿肽加定衍生物 - Google Patents

去氧阿肽加定衍生物 Download PDF

Info

Publication number
CN102348718B
CN102348718B CN201080012769.5A CN201080012769A CN102348718B CN 102348718 B CN102348718 B CN 102348718B CN 201080012769 A CN201080012769 A CN 201080012769A CN 102348718 B CN102348718 B CN 102348718B
Authority
CN
China
Prior art keywords
compounds
compound
deoxyactagardine
administration
clostridium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080012769.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102348718A (zh
Inventor
舒尔得·尼古拉斯·瓦德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novacta Biosystems Ltd
Original Assignee
Novacta Biosystems Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacta Biosystems Ltd filed Critical Novacta Biosystems Ltd
Publication of CN102348718A publication Critical patent/CN102348718A/zh
Application granted granted Critical
Publication of CN102348718B publication Critical patent/CN102348718B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
CN201080012769.5A 2009-01-14 2010-01-12 去氧阿肽加定衍生物 Expired - Fee Related CN102348718B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14449009P 2009-01-14 2009-01-14
US61/144,490 2009-01-14
PCT/GB2010/000042 WO2010082018A1 (en) 2009-01-14 2010-01-12 Deoxyactagardine derivatives

Publications (2)

Publication Number Publication Date
CN102348718A CN102348718A (zh) 2012-02-08
CN102348718B true CN102348718B (zh) 2015-06-03

Family

ID=42110329

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080012769.5A Expired - Fee Related CN102348718B (zh) 2009-01-14 2010-01-12 去氧阿肽加定衍生物

Country Status (22)

Country Link
US (2) US8283371B2 (cg-RX-API-DMAC10.html)
EP (1) EP2387580B1 (cg-RX-API-DMAC10.html)
JP (1) JP5719312B2 (cg-RX-API-DMAC10.html)
KR (1) KR20110119699A (cg-RX-API-DMAC10.html)
CN (1) CN102348718B (cg-RX-API-DMAC10.html)
AU (1) AU2010205472B2 (cg-RX-API-DMAC10.html)
CA (1) CA2749278A1 (cg-RX-API-DMAC10.html)
DK (1) DK2387580T3 (cg-RX-API-DMAC10.html)
EA (1) EA021683B1 (cg-RX-API-DMAC10.html)
ES (1) ES2520165T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20141084T1 (cg-RX-API-DMAC10.html)
IL (1) IL213927A0 (cg-RX-API-DMAC10.html)
MX (1) MX2011007313A (cg-RX-API-DMAC10.html)
NZ (1) NZ594011A (cg-RX-API-DMAC10.html)
PL (1) PL2387580T3 (cg-RX-API-DMAC10.html)
PT (1) PT2387580E (cg-RX-API-DMAC10.html)
RS (1) RS53586B1 (cg-RX-API-DMAC10.html)
SG (1) SG172944A1 (cg-RX-API-DMAC10.html)
SI (1) SI2387580T1 (cg-RX-API-DMAC10.html)
TW (1) TWI453029B (cg-RX-API-DMAC10.html)
WO (1) WO2010082018A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201104991B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
DK2387580T3 (da) 2009-01-14 2014-10-13 Novacta Biosystems Ltd Deoxyactagardinderivater
EA020733B1 (ru) 2009-02-04 2015-01-30 Новакта Биосистемс Лимитед Производные актагардина
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
GB201013507D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013509D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013508D0 (en) * 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201213434D0 (en) 2012-07-27 2012-09-12 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0195359A2 (en) * 1985-03-22 1986-09-24 GRUPPO LEPETIT S.p.A. Basic monocarboxyamide derivatives of actagardine having antibiotic activity
WO2007083112A2 (en) * 2006-01-17 2007-07-26 Novacta Biosystems Limited Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) * 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5304540A (en) 1988-06-22 1994-04-19 Applied Microbiology, Inc. Pharmaceutical bacteriocin compositions and methods for using the same
IN167138B (cg-RX-API-DMAC10.html) * 1988-08-17 1990-09-01 Hoechst India
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1260505B (it) 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
IL107887A (en) * 1992-12-08 2003-07-06 Ambi Inc Stabilized lanthionine containing bacteriocin compositions
US5512269A (en) 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
ATE255165T1 (de) 1994-09-12 2003-12-15 Aventis Pharma Gmbh Rekombinantes mersacidin und verfahren zu seiner herstellung
US5866539A (en) 1995-06-23 1999-02-02 Ambi Inc. Method for the control of antibiotic-resistant gram positive bacteria and treatment of infection
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5958873A (en) 1997-06-09 1999-09-28 University Of Cincinnati Oral formulation for treatment of bacteria-induced diseases of the colon
US5985823A (en) * 1997-06-09 1999-11-16 Ambi Inc. Method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
DE19745583A1 (de) 1997-10-15 1999-04-22 Hoechst Marion Roussel De Gmbh Neues Lantibiotikum verwandt mit Actagardine, Verfahren zur Herstellung und Verwendung derselben
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
GB0110432D0 (en) 2001-04-27 2001-06-20 Plant Bioscience Ltd Lantibiotic production
WO2002103010A1 (en) 2001-06-14 2002-12-27 Plant Bioscience Limited Methods and materials for targeted gene disruption in actinomycete bacteria
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
EP1558746A4 (en) 2002-10-10 2006-11-22 Molichem Medicines Inc DURAMYCIN-CODING NUCLEIC ACIDS
US7351687B2 (en) 2003-07-18 2008-04-01 Vicuron Pharmaceuticals, Inc. Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof
ATE356143T1 (de) 2003-07-18 2007-03-15 Vicuron Pharm Inc Antibiotikum 107891, dessen faktoren a1 und a2, pharmazeutisch unbedenkliche salze und zusammensetzungen, und anwendung davon
GB0406870D0 (en) 2004-03-26 2004-04-28 Novacta Biosystems Ltd Improvements relating to the production of lantibiotics
EP1928900A1 (en) 2005-09-27 2008-06-11 Novacta Biosystems Limited Variants of the lantibiotic mersacidin and their use
CA2667167C (en) 2006-10-27 2014-02-18 Pfizer Products Inc. Hydroxypropyl methyl cellulose hard capsules and process of manufacture
WO2008151434A1 (en) 2007-06-12 2008-12-18 The University Of British Columbia Small cationic antimicrobial peptides
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
AU2008364202A1 (en) 2008-11-24 2011-07-07 Sentinella Pharmaceuticals, Inc. ("Sentinella") Lantibiotic carboxyamide derivatives with enhanced antibacterial activity
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
DK2387580T3 (da) 2009-01-14 2014-10-13 Novacta Biosystems Ltd Deoxyactagardinderivater
EA020733B1 (ru) 2009-02-04 2015-01-30 Новакта Биосистемс Лимитед Производные актагардина

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0195359A2 (en) * 1985-03-22 1986-09-24 GRUPPO LEPETIT S.p.A. Basic monocarboxyamide derivatives of actagardine having antibiotic activity
WO2007083112A2 (en) * 2006-01-17 2007-07-26 Novacta Biosystems Limited Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SYNTHESIS AND BIOLOGICAL ACTIVITY OF SOME AMIDE DERIVATIVES OF THE LANTIBIOTIC ACTAGARDINE;Adriano Malabarba ET AL;《THE JOURNAL OF ANTIBIOTICS》;19901231;第43卷(第9期);1089-1097 *
THE TETRACYCLIC LANTIBIOTIC ACTAGARDINE H-NMR AND C-NMR ASSIGNMENTS AND REVISED PRIMARY STRUCTURE;ZIMMERMANN N ET AL;《EUROPEAN JOURNAL OF BIOCHEMISTRY》;19951231;第228卷(第3期);786-797 *

Also Published As

Publication number Publication date
JP5719312B2 (ja) 2015-05-13
IL213927A0 (en) 2011-07-31
ES2520165T3 (es) 2014-11-11
TW201029661A (en) 2010-08-16
ZA201104991B (en) 2013-10-31
RS53586B1 (sr) 2015-02-27
EP2387580A1 (en) 2011-11-23
US20100179207A1 (en) 2010-07-15
HRP20141084T1 (hr) 2015-02-13
EA201190071A1 (ru) 2012-06-29
PT2387580E (pt) 2014-10-30
JP2012515195A (ja) 2012-07-05
WO2010082018A1 (en) 2010-07-22
NZ594011A (en) 2013-12-20
US20120277145A1 (en) 2012-11-01
EP2387580B1 (en) 2014-08-13
AU2010205472A1 (en) 2011-07-28
SG172944A1 (en) 2011-08-29
EA021683B1 (ru) 2015-08-31
SI2387580T1 (sl) 2014-11-28
KR20110119699A (ko) 2011-11-02
DK2387580T3 (da) 2014-10-13
MX2011007313A (es) 2011-08-04
US8741945B2 (en) 2014-06-03
CN102348718A (zh) 2012-02-08
AU2010205472B2 (en) 2013-03-14
CA2749278A1 (en) 2010-07-22
US8283371B2 (en) 2012-10-09
TWI453029B (zh) 2014-09-21
PL2387580T3 (pl) 2015-01-30

Similar Documents

Publication Publication Date Title
JP5719312B2 (ja) デオキシアクタガルジン誘導体
TWI504610B (zh) 阿肽加定衍生物、其製備方法及其用途
KR20010085857A (ko) 글리코펩티드 유도체 및 그를 포함하는 약학적 조성물
US20240165245A1 (en) Multivalent peptoid oligomers, pharmaceutical compositions and methods of using same
WO2010082019A1 (en) Actagardine derivatives, and pharmaceutical use thereof
CN101959849A (zh) 作为抗菌剂的新型半合成糖肽
US20130165641A1 (en) 6,11-bridged biaryl macrolides
US20090264345A1 (en) Macrocyclic peptides and methods for making and using them
EP2010203A2 (en) Macrocyclic peptides and methods for making and using them
CA2379058A1 (en) Pseudomycin prodrugs
CN101137665A (zh) 脱氧九酯肽类
CA2379851A1 (en) Pseudomycin n-acyl side-chain analogs
JP7334183B2 (ja) グリコシルトランスフェラーゼ阻害剤
WO2011095768A1 (en) Lantibiotic salts
CN101153053A (zh) 骨生肽、其制备方法和其药物组合物与用途
CN109415378B (zh) 水溶性Epothilone衍生物及其制备方法
WO2012020220A1 (en) Compounds
HUP0202267A2 (en) Pseudomycin amide and ester analogs, method for their preparation and pharmaceutical compositions comprising thereof
WO2012020221A1 (en) Compounds
WO2012020222A1 (en) Compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150603

Termination date: 20170112

CF01 Termination of patent right due to non-payment of annual fee